Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab

Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory disease associated with joint destruction. Tocilizumab (TCZ) is a humanized monoclonal anti-interleukin-6 receptor antibody that was initially developed for use as an intravenous (IV) infusion. Previous studies have shown that TCZ-IV...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakashima, Yasuharu, Kondo, Masakazu, Miyahara, Hisaaki, Iwamoto, Yukihide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094568/
https://www.ncbi.nlm.nih.gov/pubmed/25045250
http://dx.doi.org/10.2147/DDDT.S52099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094568/
https://www.ncbi.nlm.nih.gov/pubmed/25045250
http://dx.doi.org/10.2147/DDDT.S52099

Ejemplares similares